CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
temozolomidedrug
Likely dose
temozolomide 200mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00582075
NCT00582075Phase 2Completed
CompareCT.gov

Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases

University of Alabama at Birmingham·interventional·Posted Dec 28, 2007·Updated Mar 27, 2023

In Brief

A Phase 2 clinical trial evaluating temozolomide for Cancer and Brain Metastases. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The protocol is designed to determine the efficacy of temozolomide in preventing the development of new brain metastases within the first year in patients undergoing stereotactic radiation for newly diagnosed brain metastases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Brain Metastases
CountriesUnited States
CollaboratorsIntegrated Therapeutics Group

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2007
Enrollment StartJul 1, 2002
Primary CompletionOct 1, 2008
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 18.5 years ago

Interventions

temozolomidedrug

TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5